Vascular proliferation is increased in basal-like breast cancer

Breast Cancer Research and Treatment

Volumn 130, Issue 3, 2011, Pages 1063-1071

  Nalwoga, Hawa ^a,b   Arnes, Jarle B ^a   Stefansson, Ingunn M ^a,c   Wabinga, Henry ^b   Foulkes, William D ^d   Akslen, Lars A ^a,c  

^a UNIVERSITY OF BERGEN   (Norway)

^b MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Basal like; Breast cancer; Tumor angiogenesis

Indexed keywords

ANTINEOPLASTIC AGENT; BLOOD CLOTTING FACTOR 8; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; P CADHERIN; PROTEIN P63;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CASE STUDY; CELL PROLIFERATION; ENDOTHELIUM CELL; FEMALE; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOLECULAR BIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MARKERS, BIOLOGICAL;

EID: 82255191709     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1740-7     Document Type: Article

References (47)

1. T Sorlie CM Perou R Tibshirani T Aas S Geisler H Johnsen T Hastie MB Eisen M van de Rijn SS Jeffrey T Thorsen H Quist JC Matese PO Brown D Botstein PE Lonning AL Borresen-Dale 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 19 10869 10874 10.1073/pnas.191367098 11553815 10.1073/pnas.191367098 1:CAS:528:DC%2BD3MXntVGmsbo%3D (Pubitemid 32878711)
2. EA Rakha JS Reis-Filho IO Ellis 2008 Basal-like breast cancer: a critical review J Clin Oncol 26 15 2568 2581 10.1200/JCO.2007.13.1748 18487574 10.1200/JCO.2007.13.1748
3. M Tischkowitz JS Brunet LR Begin DG Huntsman MC Cheang LA Akslen TO Nielsen WD Foulkes 2007 Use of immunohistochemical markers can refine prognosis in triple negative breast cancer BMC Cancer 7 134 10.1186/1471-2407-7-134 17650314 10.1186/1471-2407-7-134 (Pubitemid 47272190)
4. DG Hicks SM Short NL Prescott SM Tarr KA Coleman BJ Yoder JP Crowe TK Choueiri AE Dawson GT Budd RR Tubbs G Casey RJ Weil 2006 Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR Am J Surg Pathol 30 9 1097 1104 10.1097/01.pas.0000213306.05811.b9 16931954 (Pubitemid 44299342)
5. J Folkman 1990 What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82 1 4 6 10.1093/jnci/82.1.4 1688381 10.1093/jnci/82.1.4 1:STN:280:DyaK3c%2FnvF2qug%3D%3D (Pubitemid 20020880)
6. SB Fox DG Generali AL Harris 2007 Breast tumour angiogenesis Breast Cancer Res 9 6 216 10.1186/bcr1796 18190723 10.1186/bcr1796
7. D Hanahan RA Weinberg 2000 The hallmarks of cancer Cell 100 1 57 70 10.1016/S0092-8674(00)81683-9 10647931 10.1016/S0092-8674(00)81683-9 1:CAS:528:DC%2BD3cXks1CktA%3D%3D (Pubitemid 30046295)
8. N Lopes B Sousa D Vieira F Milanezi F Schmitt 2009 Vessel density assessed by endoglin expression in breast carcinomas with different expression profiles Histopathology 55 5 594 599 10.1111/j.1365-2559.2009.03417.x 19912365 10.1111/j.1365-2559.2009.03417.x
9. A Ribeiro-Silva F Ribeiro do Vale S Zucoloto 2006 Vascular endothelial growth factor expression in the basal subtype of breast carcinoma Am J Clin Pathol 125 4 512 518 10.1309/D744C4NM15J3B00D 16627261 1:CAS:528: DC%2BD28XjslGmsL4%3D
10. JR Goffin O Straume PO Chappuis JS Brunet LR Begin N Hamel N Wong LA Akslen WD Foulkes 2003 Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer Br J Cancer 89 6 1031 1034 10.1038/sj.bjc.6601195 12966421 10.1038/sj.bjc.6601195 1:CAS:528:DC%2BD3sXntVKgu74%3D (Pubitemid 37239207)
11. O Straume PO Chappuis HB Salvesen OJ Halvorsen SA Haukaas JR Goffin LR Begin WD Foulkes LA Akslen 2002 Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers Cancer Res 62 23 6808 6811 12460889 1:CAS:528:DC%2BD38XpsVahsrs%3D (Pubitemid 35424063)
12. WD Foulkes JS Brunet IM Stefansson O Straume PO Chappuis LR Begin N Hamel JR Goffin N Wong M Trudel L Kapusta P Porter LA Akslen 2004 The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid- microvascular-proliferation+) phenotype of BRCA1-related breast cancer Cancer Res 64 3 830 835 10.1158/0008-5472.CAN-03-2970 14871808 10.1158/0008-5472.CAN- 03-2970 1:CAS:528:DC%2BD2cXhtFCgtLo%3D (Pubitemid 38176880)
13. L Hlatky P Hahnfeldt J Folkman 2002 Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us J Natl Cancer Inst 94 12 883 893 10.1093/jnci/94.12.883 12072542 10.1093/jnci/94.12.883 (Pubitemid 34778087)
14. K Gravdal OJ Halvorsen SA Haukaas LA Akslen 2009 Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer Cancer Res 69 11 4708 4715 10.1158/0008-5472.CAN-08-4417 19487287 10.1158/0008-5472.CAN-08-4417 1:CAS:528:DC%2BD1MXmsFGluro%3D
15. IM Stefansson HB Salvesen LA Akslen 2006 Vascular proliferation is important for clinical progress of endometrial cancer Cancer Res 66 6 3303 3309 10.1158/0008-5472.CAN-05-1163 16540684 10.1158/0008-5472.CAN-05-1163 1:CAS:528:DC%2BD28XitlertLg%3D
16. H Nalwoga JB Arnes H Wabinga LA Akslen 2010 Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer Br J Cancer 102 2 369 375 10.1038/sj.bjc.6605488 20010944 10.1038/sj.bjc.6605488 1:CAS:528: DC%2BC3cXntlKisA%3D%3D
17. WD Foulkes IM Stefansson PO Chappuis LR Begin JR Goffin N Wong M Trudel LA Akslen 2003 Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer J Natl Cancer Inst 95 19 1482 1485 10.1093/jnci/djg050 14519755 10.1093/jnci/djg050 1:CAS:528:DC%2BD3sXnvVCjtrk%3D (Pubitemid 37279334)
18. JB Arnes LR Begin I Stefansson JS Brunet TO Nielsen WD Foulkes LA Akslen 2009 Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer J Clin Pathol 62 2 139 146 10.1136/jcp.2008.056291 18682421 10.1136/jcp.2008.056291 1:STN:280: DC%2BD1M7gs1Klsw%3D%3D
19. H Nalwoga JB Arnes H Wabinga LA Akslen 2008 Expression of EGFR and c-kit is associated with the basal-like phenotype in breast carcinomas of African women APMIS 116 6 515 525 10.1111/j.1600-0463.2008.01024.x 18754326 10.1111/j.1600-0463.2008.01024.x 1:CAS:528:DC%2BD1cXpslKitrw%3D
20. IB Engelsen I Stefansson LA Akslen HB Salvesen 2006 Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas Am J Obstet Gynecol 195 4 979 986 10.1016/j.ajog.2006.02. 045 16677592 10.1016/j.ajog.2006.02.045 1:CAS:528:DC%2BD28XpvV2ktrg%3D (Pubitemid 44415644)
21. IM Stefansson HB Salvesen LA Akslen 2006 Loss of p63 and cytokeratin 5/6 expression is associated with more aggressive tumors in endometrial carcinoma patients Int J Cancer 118 5 1227 1233 10.1002/ijc.21415 16152605 10.1002/ijc.21415 1:CAS:528:DC%2BD28XhsFektr8%3D (Pubitemid 43185610)
22. JB Arnes JS Brunet I Stefansson LR Begin N Wong PO Chappuis LA Akslen WD Foulkes 2005 Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer Clin Cancer Res 11 11 4003 4011 10.1158/1078-0432. CCR-04-2064 15930334 10.1158/1078-0432.CCR-04-2064 1:CAS:528: DC%2BD2MXks1Gksr8%3D (Pubitemid 40791563)
23. ZQ Yuan LR Begin N Wong JS Brunet M Trifiro PH Gordon L Pinsky WD Foulkes 1999 The effect of the I1307K APC polymorphism on the clinicopathological features and natural history of breast cancer Br J Cancer 81 5 850 854 10.1038/sj.bjc.6690775 10555757 10.1038/sj.bjc.6690775 1:CAS:528: DyaK1MXnsFGgtbg%3D (Pubitemid 29504696)
24. LA Carey CM Perou CA Livasy LG Dressler D Cowan K Conway G Karaca MA Troester CK Tse S Edmiston SL Deming J Geradts MC Cheang TO Nielsen PG Moorman HS Earp RC Millikan 2006 Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study JAMA 295 21 2492 2502 10.1001/jama.295.21.2492 16757721 10.1001/jama.295.21.2492 1:CAS:528:DC%2BD28XlsV2rtLw%3D (Pubitemid 43854964)
25. H Sihto J Lundin T Lehtimaki M Sarlomo-Rikala R Butzow K Holli L Sailas V Kataja M Lundin T Turpeenniemi-Hujanen J Isola P Heikkila H Joensuu 2008 Molecular subtypes of breast cancers detected in mammography screening and outside of screening Clin Cancer Res 14 13 4103 4110 10.1158/1078-0432.CCR-07- 5003 18593987 10.1158/1078-0432.CCR-07-5003 1:CAS:528:DC%2BD1cXnvFylu74%3D
26. XR Yang ME Sherman DL Rimm J Lissowska LA Brinton B Peplonska, et al. 2007 Differences in risk factors for breast cancer molecular subtypes in a population-based study Cancer Epidemiol Biomarkers Prev 16 3 439 443 10.1158/1055-9965.EPI-06-0806 17372238 10.1158/1055-9965.EPI-06-0806 1:CAS:528:DC%2BD2sXjt1Srt7s%3D (Pubitemid 46548646)
27. TO Nielsen FD Hsu K Jensen M Cheang G Karaca Z Hu T Hernandez-Boussard C Livasy D Cowan L Dressler LA Akslen J Ragaz AM Gown CB Gilks MV van de Rijn CM Perou 2004 Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 10 16 5367 5374 10.1158/1078-0432.CCR-04-0220 15328174 10.1158/1078-0432.CCR-04-0220 1:CAS:528:DC%2BD2cXmvFSlt7k%3D (Pubitemid 39100473)
28. N Weidner JP Semple WR Welch J Folkman 1991 Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma N Engl J Med 324 1 1 8 1701519 10.1056/NEJM199101033240101 1:STN:280:DyaK3M%2FnsVWquw%3D%3D
29. JT Chi Z Wang DS Nuyten EH Rodriguez ME Schaner A Salim Y Wang GB Kristensen A Helland AL Borresen-Dale A Giaccia MT Longaker T Hastie GP Yang MJ van de Vijver PO Brown 2006 Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers PLoS Med 3 3 e47 10.1371/journal.pmed.0030047 16417408 10.1371/journal.pmed.0030047
30. SF Dent 2009 The role of VEGF in triple-negative breast cancer: where do we go from here? Ann Oncol 20 10 1615 1617 10.1093/annonc/mdp410 19690059 10.1093/annonc/mdp410 1:STN:280:DC%2BD1MnktVCnsg%3D%3D
31. Z Hu C Fan C Livasy X He DS Oh MG Ewend LA Carey S Subramanian R West F Ikpatt OI Olopade M van de Rijn CM Perou 2009 A compact VEGF signature associated with distant metastases and poor outcomes BMC Med 7 9 10.1186/1741-7015-7-9 19291283 10.1186/1741-7015-7-9
32. BK Linderholm H Hellborg U Johansson G Elmberger L Skoog J Lehtio R Lewensohn 2009 Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer Ann Oncol 20 10 1639 1646 10.1093/annonc/mdp062 19549711 10.1093/annonc/mdp062 1:STN:280:DC%2BD1MnjvFyitQ%3D%3D
33. Y Nieto J Woods F Nawaz A Baron RB Jones EJ Shpall S Nawaz 2007 Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy Br J Cancer 97 3 391 397 10.1038/sj.bjc.6603875 17609662 10.1038/sj.bjc.6603875 1:CAS:528: DC%2BD2sXotlSgtro%3D (Pubitemid 47196747)
34. SM Wilhelm C Carter L Tang D Wilkie A McNabola H Rong C Chen X Zhang P Vincent M McHugh Y Cao J Shujath S Gawlak D Eveleigh B Rowley L Liu L Adnane M Lynch D Auclair I Taylor R Gedrich A Voznesensky B Riedl LE Post G Bollag PA Trail 2004 BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 19 7099 7109 10.1158/0008-5472.CAN- 04-1443 15466206 10.1158/0008-5472.CAN-04-1443 1:CAS:528:DC%2BD2cXotFalsbk%3D (Pubitemid 39331023)
35. KA Hoadley VJ Weigman C Fan LR Sawyer X He MA Troester CI Sartor T Rieger-House PS Bernard LA Carey CM Perou 2007 EGFR associated expression profiles vary with breast tumor subtype BMC Genomics 8 258 10.1186/1471-2164-8- 258 17663798 10.1186/1471-2164-8-258 (Pubitemid 47559211)
36. M Senoo Y Matsumura S Habu 2002 TAp63gamma (p51A) and dNp63alpha (p73L), two major isoforms of the p63 gene, exert opposite effects on the vascular endothelial growth factor (VEGF) gene expression Oncogene 21 16 2455 2465 10.1038/sj.onc.1205330 11971180 10.1038/sj.onc.1205330 1:CAS:528: DC%2BD38Xjtlemtb0%3D (Pubitemid 34438098)
37. M Barbareschi L Pecciarini MG Cangi E Macri A Rizzo G Viale C Doglioni 2001 p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast Am J Surg Pathol 25 8 1054 1060 11474290 10.1097/00000478-200108000-00010 1:STN:280:DC%2BD3MvislShug%3D%3D (Pubitemid 32685903)
38. CO Leong N Vidnovic MP DeYoung D Sgroi LW Ellisen 2007 The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers J Clin Investig 117 5 1370 1380 10.1172/JCI30866 17446929 10.1172/JCI30866 1:CAS:528:DC%2BD2sXlt1Omtb4%3D (Pubitemid 46718425)
39. I Matos R Dufloth M Alvarenga LC Zeferino F Schmitt 2005 p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas Virchows Arch 447 4 688 694 10.1007/s00428-005-0010-7 16012853 10.1007/s00428-005-0010-7 1:CAS:528:DC%2BD2MXhtFKqt7zM (Pubitemid 41571183)
40. A Fourati F Khomsi MV El May K Rahal A Gamoudi H Boussen M Ben Abdallah A El May 2007 Correlation between P53 expression and CD34 angiogenic factor in Tunisian breast cancer Tunis Med 85 2 105 108 17665654 (Pubitemid 46761645)
41. R Ravi B Mookerjee ZM Bhujwalla CH Sutter D Artemov Q Zeng LE Dillehay A Madan GL Semenza A Bedi 2000 Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha Genes Dev 14 1 34 44 10.1101/gad.14.1.34 10640274 1:CAS:528:DC%2BD3cXntFGkuw%3D%3D (Pubitemid 30051577)
42. OV Volpert V Stellmach N Bouck 1995 The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression Breast Cancer Res Treat 36 2 119 126 10.1007/BF00666034 8534861 10.1007/BF00666034 1:STN:280:DyaK28%2FkvFOqtQ%3D%3D
43. E Laughner P Taghavi K Chiles PC Mahon GL Semenza 2001 HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression Mol Cell Biol 21 12 3995 4004 10.1128/MCB.21.12.3995-4004.2001 11359907 10.1128/MCB.21.12.3995-4004.2001 1:CAS:528:DC%2BD3MXktFWgtL4%3D (Pubitemid 32476461)
44. MI Koukourakis C Manolas G Minopoulos A Giatromanolaki E Sivridis 2003 Angiogenesis relates to estrogen receptor negativity, c-erbB-2 overexpression and early relapse in node-negative ductal carcinoma of the breast Int J Surg Pathol 11 1 29 34 10.1177/106689690301100107 12598915 10.1177/106689690301100107 1:CAS:528:DC%2BD3sXitVygu74%3D (Pubitemid 36227986)
45. S Vamesu 2007 Angiogenesis and c-erbB-2 (HER2/neu) overexpression status in primary breast cancer patients: an analysis of 158 needle core biopsies Rom J Morphol Embryol 48 2 121 129 480207121129[pii] 17641798 1:STN:280: DC%2BD2svitlCisQ%3D%3D
46. T Kato S Kameoka T Kimura T Nishikawa T Kasajima 2001 Angiogenesis and blood vessel invasion as prognostic indicators for node-negative breast cancer Breast Cancer Res Treat 65 3 203 215 10.1023/A:1010668616265 11336242 10.1023/A:1010668616265 1:STN:280:DC%2BD3M3mt12mtQ%3D%3D (Pubitemid 32331366)
47. A Morabito R Sarmiento P Bonginelli G Gasparini 2004 Antiangiogenic strategies, compounds, and early clinical results in breast cancer Crit Rev Oncol Hematol 49 2 91 107 10.1016/S1040-8428(03)00168-9 15012971 10.1016/S1040-8428(03)00168-9 (Pubitemid 38175437)